Collaborative Update of a Rule-based Expert System for HIV-1 Genotypic Resistance Test Interpretation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 29

PMID 28753637

Citations 21

Authors

Roger Paredes

Philip L Tzou

Gert van Zyl

Geoff Barrow

Ricardo Camacho

Sergio Carmona

Philip M Grant

Ravindra K Gupta

Raph L Hamers

P Richard Harrigan

Michael R Jordan

Rami Kantor

David A Katzenstein

Daniel R Kuritzkes

Frank Maldarelli

Dan Otelea

Carole L Wallis

Jonathan M Schapiro

Robert W Shafer

Affiliations

Soon will be listed here.

Abstract

Introduction: HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment guidelines evolve.

Methods: An expert panel was created to provide recommendations for the update of the Stanford HIV Drug Resistance Database (HIVDB) GRT-IS. The panel was polled on the ARVs to be included in a GRT report, and the drug-resistance interpretations associated with 160 drug-resistance mutation (DRM) pattern-ARV combinations. The DRM pattern-ARV combinations included 52 nucleoside RT inhibitor (NRTI) DRM pattern-ARV combinations (13 patterns x 4 NRTIs), 27 nonnucleoside RT inhibitor (NNRTI) DRM pattern-ARV combinations (9 patterns x 3 NNRTIs), 39 protease inhibitor (PI) DRM pattern-ARV combinations (13 patterns x 3 PIs) and 42 integrase strand transfer inhibitor (INSTI) DRM pattern-ARV combinations (14 patterns x 3 INSTIs).

Results: There was universal agreement that a GRT report should include the NRTIs lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir disoproxil fumarate; the NNRTIs efavirenz, etravirine, nevirapine, and rilpivirine; the PIs atazanavir/r, darunavir/r, and lopinavir/r (with "/r" indicating pharmacological boosting with ritonavir or cobicistat); and the INSTIs dolutegravir, elvitegravir, and raltegravir. There was a range of opinion as to whether the NRTIs stavudine and didanosine and the PIs nelfinavir, indinavir/r, saquinavir/r, fosamprenavir/r, and tipranavir/r should be included. The expert panel members provided highly concordant DRM pattern-ARV interpretations with only 6% of NRTI, 6% of NNRTI, 5% of PI, and 3% of INSTI individual expert interpretations differing from the expert panel median by more than one resistance level. The expert panel median differed from the HIVDB 7.0 GRT-IS for 20 (12.5%) of the 160 DRM pattern-ARV combinations including 12 NRTI, two NNRTI, and six INSTI pattern-ARV combinations. Eighteen of these differences were updated in HIVDB 8.1 GRT-IS to reflect the expert panel median. Additionally, HIVDB users are now provided with the option to exclude those ARVs not considered to be universally required.

Conclusions: The HIVDB GRT-IS was updated through a collaborative process to reflect changes in HIV drug resistance knowledge, treatment guidelines, and expert opinion. Such a process broadens consensus among experts and identifies areas requiring further study.

Citing Articles

Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1.

Di Teodoro G, Pirkl M, Incardona F, Vicenti I, Sonnerborg A, Kaiser R Bioinformatics. 2024; 40(6).

PMID: 38775719 PMC: 11153833. DOI: 10.1093/bioinformatics/btae327.

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.

Maruapula D, Moraka N, Bareng O, Mokgethi P, Choga W, Seatla K J Antimicrob Chemother. 2023; 78(10):2489-2495.

PMID: 37585352 PMC: 10545497. DOI: 10.1093/jac/dkad258.

We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy.

Kantor R, Gupta R Lancet HIV. 2023; 10(3):e202-e208.

PMID: 36610438 PMC: 10067973. DOI: 10.1016/S2352-3018(22)00327-7.

Highly Ambiguous HIV-1 Pol Positions Encoding Multiple Amino Acids Usually Result from Antiviral or Immune Selection Pressure.

Tao K, Rhee S, Tzou P, Holmes S, Shafer R AIDS Res Hum Retroviruses. 2022; 39(3):119-123.

PMID: 36515174 PMC: 9986027. DOI: 10.1089/AID.2022.0094.

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program.

Tzou P, Tao K, Sahoo M, Kosakovsky Pond S, Pinsky B, Shafer R J Clin Virol. 2022; 157:105323.

PMID: 36334368 PMC: 9595491. DOI: 10.1016/j.jcv.2022.105323.

References

King M, Rode R, Cohen-Codar I, Calvez V, Marcelin A, Hanna G . Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007; 51(9):3067-74. PMC: 2043245. DOI: 10.1128/AAC.00388-07. View

Molina J, LaMarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu Y . Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2011; 12(1):27-35. DOI: 10.1016/S1473-3099(11)70249-3. View

Naeger L, Struble K . Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS. 2007; 21(2):179-85. DOI: 10.1097/QAD.0b013e3280119213. View

Vercauteren J, Beheydt G, Prosperi M, Libin P, Imbrechts S, Camacho R . Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS One. 2013; 8(4):e61436. PMC: 3629176. DOI: 10.1371/journal.pone.0061436. View

Tang M, Liu T, Shafer R . The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55(2):98-101. PMC: 7068798. DOI: 10.1159/000331998. View

Underwood M, Johns B, Sato A, Martin J, Deeks S, Fujiwara T . The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012; 61(3):297-301. PMC: 3804312. DOI: 10.1097/QAI.0b013e31826bfd02. View

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown K, Ferris R . In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2010; 55(2):813-21. PMC: 3028777. DOI: 10.1128/AAC.01209-10. View

Canducci F, Ceresola E, Boeri E, Spagnuolo V, Cossarini F, Castagna A . Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011; 204(11):1811-5. DOI: 10.1093/infdis/jir636. View

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

10.

Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N . Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 2003; 17(8):1151-6. DOI: 10.1097/00002030-200305230-00006. View

11.

Larder B, Wang D, Revell A, Montaner J, Harrigan R, de Wolf F . The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther. 2007; 12(1):15-24. View

12.

Munir S, Thierry E, Malet I, Subra F, Calvez V, Marcelin A . G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother. 2014; 70(3):739-49. DOI: 10.1093/jac/dku474. View

13.

Lanier E, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G . Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004; 9(1):37-45. DOI: 10.1177/135965350400900102. View

14.

Whitcomb J, Parkin N, Chappey C, Hellmann N, Petropoulos C . Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003; 188(7):992-1000. DOI: 10.1086/378281. View

15.

Fransen S, Gupta S, Frantzell A, Petropoulos C, Huang W . Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol. 2012; 86(13):7249-55. PMC: 3416338. DOI: 10.1128/JVI.06618-11. View

16.

Walmsley S, Kelly D, Tseng A, Humar A, Harrigan P . Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. AIDS. 2001; 15(12):1581-4. DOI: 10.1097/00002030-200108170-00019. View

17.

Rhee S, Fessel W, Liu T, Marlowe N, Rowland C, Rode R . Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis. 2009; 200(3):453-63. PMC: 4774893. DOI: 10.1086/600073. View

18.

Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg M . Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol. 2015; 89(8):4681-4. PMC: 4442391. DOI: 10.1128/JVI.03485-14. View

19.

Abram M, Ram R, Margot N, Barnes T, White K, Callebaut C . Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS One. 2017; 12(2):e0172206. PMC: 5315389. DOI: 10.1371/journal.pone.0172206. View

20.

Lepik K, Harrigan P, Yip B, Wang L, Robbins M, Zhang W . Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017; 31(10):1425-1434. DOI: 10.1097/QAD.0000000000001494. View